Compare Novavax Inc (NVAX) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Verisign, Inc. — how do they compare? Novavax Inc trades at $8.06 (market cap $1.30B), while Verisign, Inc. trades at $277.5 (market cap $25.26B). The key difference: Verisign, Inc. is far larger — about 19.4× Novavax Inc's market cap, and Verisign, Inc. pays a 1.17% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | VRSN | |
|---|---|---|
Market Cap | $1.30B | $25.26B |
Sector | Health | Technology |
52-Week High | $11.19 | $310.00 |
52-Week Low | $6.22 | $211.49 |
Enterprise Value | $800.50M | $26.50B |
Dividend Yield | — | 1.17% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
